1-7 of 7
Lakshmi Nayak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma

Fabio M. Iwamoto, Shyam K. Tanguturi, Lakshmi Nayak, Tony J. Wang, Arati Desai, Robert A. Lustig, Stephen Bagley, Eric T. Wong, Lauren M. Hertan, Christine McCluskey, Julia Hayden, Alona Muzikansky, Shreya Nakhawa, Julia Japo, Connor C. Bossi, Maxime Meylan, Ye Tian, Graham L. Barlow, Paul Speliakos, Georges Ayoub, David M. Meredith, Keith L. Ligon, Daphne Haas-Kogan, Kun Huang, Kai W. Wucherpfennig, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 316–327.
https://doi.org/10.1158/1078-0432.CCR-24-1629
Published: 17 January 2025
View article titled, Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Open the PDF for Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Mary Jane Lim-Fat, J. Bryan Iorgulescu, Rifaquat Rahman, Varun Bhave, Alona Muzikansky, Eleanor Woodward, Sydney Whorral, Marie Allen, Mehdi Touat, Xiaomei Li, Gongwen Xy, Jay Patel, Elizabeth R. Gerstner, Jayashree Kalpathy-Cramer, Gilbert Youssef, Ugonma Chukwueke, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q. Lee, David A. Reardon, Rameen Beroukhim, Raymond Y. Huang, Wenya Linda Bi, Keith L. Ligon, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-23-3018
Published: 01 April 2024
View article titled, Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Open the PDF for Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients

K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3017–3025.
https://doi.org/10.1158/1078-0432.CCR-23-0203
Published: 15 August 2023
View article titled, Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
Open the PDF for Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2567–2578.
https://doi.org/10.1158/1078-0432.CCR-21-4064
Published: 13 June 2022
View article titled, Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Open the PDF for Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1048–1057.
https://doi.org/10.1158/1078-0432.CCR-20-2500
Published: 15 February 2021
View article titled, Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Open the PDF for Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma

Eudocia Q. Lee, Dan G. Duda, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, Debra LaFrankie, Jennifer Stefanik, Trupti Vardam, Katrina H. Smith, Christine McCluskey, Sarah Gaffey, Tracy T. Batchelor, Rakesh K. Jain, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4643–4649.
https://doi.org/10.1158/1078-0432.CCR-18-1025
Published: 01 October 2018
View article titled, Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Open the PDF for Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma in another window
Journal Articles

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

Raymond Y. Huang, Rifaquat Rahman, Karla V. Ballman, Sara J. Felten, S. Keith Anderson, Benjamin M. Ellingson, Lakshmi Nayak, Eudocia Q. Lee, Lauren E. Abrey, Evanthia Galanis, David A. Reardon, Whitney B. Pope, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 575–581.
https://doi.org/10.1158/1078-0432.CCR-14-3040
Published: 31 January 2016
View article titled, The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Open the PDF for The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab in another window